3.5 Executive Committee

3.5 Executive Committee

Composition of the Executive Committee

During 2019, the Executive Committee members were:

  • Jean-Christophe Tellier: Chief Executive Officer
  • Emmanuel Caeymaex: Executive Vice President & Immunology Patient Value Unit Head
  • Jean-Luc Fleurial: Executive Vice President & Chief Talent Officer
  • Iris Löw-Friedrich: Executive Vice President Chief Medical Officer & Head of Development and Medical Patent Value Practices
  • Kirsten Lund-Jurgensen: Executive Vice President, Supply & Technology Solutions (joined in September 2019)
  • Alexander Moscho: Executive Vice President & Chief Strategy Officer
  • Dhaval Patel: Executive Vice President & Chief Scientific Officer
  • Pascale Richetta: Executive Vice President & Bone Patient Value Unit Head
  • Bill Silbey: Executive Vice President & General Counsel (joined in March 2019)
  • Bharat Tewarie: Executive Vice President & Chief Marketing Officer
  • Detlef Thielgen: Executive Vice President & Chief Financial Officer
  • Charl van Zyl: Executive Vice President & Chief Operating Officer
  • Jeff Wren: Executive Vice President & Neurology Patient Value Unit Head

As announced in July 2019, we evolved our organization and ways of working to ensure we become more agile and collaborate more transversally across our organization.This evolved organization is increasing our operational clarity and efficiency, and sets us up for truly patient-value focused launches. This evolution is reflected in the new composition of the UCB Executive Committee which became smaller, with more transversal roles across businesses and regions, and with more focus on the company’s core activity areas.

As a result of these organizational changes, Jeff Wren and Bharat Tewarie have stepped down from the Executive Committee in Q4 2019, while Alexander Moscho and Pascale Richetta stepped down in January 2020. 

As from 1 February 2020, the composition of the Executive Committee is as follows:

Jean-Christophe Tellier (portrait)

Jean-Christophe Tellier

Chief Executive Officer

1959 – French

Jean-Christophe Tellier

Chief Executive Officer

1959 – French

Joined UCB in 2011

Appointed in 2011

Appointed CEO in 2015

Main external appointments

  • President of the Board of EFPIA (European Federation of Pharmaceutical Industries and Associations)
  • Member of the Board of PhRMA (Pharmaceutical Research and Manufacturers of America)
  • Member of the Board of WELBIO (Walloon Institute for Life Lead Sciences)

Experience

Over 30 years in the pharmaceutical sector, with Ipsen and Novartis where he held several senior executive positions in different parts of the world

Emmanuel Caeymaex (portrait)

Emmanuel Caeymaex

Executive Vice President Immunology Solutions & Head of U.S.

1969 – Belgian

Emmanuel Caeymaex

Executive Vice President Immunology Solutions & Head of U.S.

1969 – Belgian

Joined UCB in 1994

Appointed in 2015

No external appointments

Experience

25 years of broad experience in biopharma­ceuticals commercial­ization, develop­ment and general management, across the world

Jean-Luc Fleurial (portrait)

Jean-Luc Fleurial

Executive Vice President & Chief Human Resources Officer

1965 – French

Jean-Luc Fleurial

Executive Vice President & Chief Human Resources Officer

1965 – French

Joined UCB in 2017

Appointed in 2017

No external appointments

Experience

Over 20 years of experience in building and implementing talent strategy across geographies and businesses, mainly with Procter&Gamble and Bristol Myers Squibb

Iris Löw-Friedrich (portrait)

Iris Löw-Friedrich

Executive Vice President & Chief Medical Officer

1960 – German

Iris Löw-Friedrich

Executive Vice President & Chief Medical Officer

1960 – German

Joined UCB in 2006

Appointed in 2008

Main external appointments

  • Member of the Supervisory Board of Evotec AG
  • Member of the Supervisory Board of Fresenius SE & Co. KGaA
  • Member of the Board of TransCelerate
  • Member of the Board of PhRMA Foundation

Experience

Physician, board-certified in internal medicine, with more than 20 years of experience in the development of medicines, with senior executive positions at Hoechst, Aventis, BASF Pharma/Knoll, Abbott and Schwarz Pharma

Kirsten Lund-Jurgensen (portrait)

Kirsten Lund-Jurgensen

Executive Vice President, Supply & Technology Solutions

1959 – German

Kirsten Lund-Jurgensen

Executive Vice President, Supply & Technology Solutions

1959 – German

Joined UCB in 2019

Appointed in 2019

No external appointments

Experience

Pharmacist, with more than 32 years of experience in manufacturing and supply of pharmaceuticals, with senior executive positions at SmithKline Beecham and Pfizer in Germany, Australia, and the U.S.

Dhaval Patel (portrait)

Dhaval Patel

Executive Vice President & Chief Scientific Officer

1961 – American

Dhaval Patel

Executive Vice President & Chief Scientific Officer

1961 – American

Joined UCB in 2017

Appointed in 2017

Main external appointments

  • Member of the Board of Inflazome
  • Member of the Board of Anokion
  • Clinical Professor at University of North Carolina at Chapel Hill

Experience

Over 30 years of experience in R&D and immunology, more specifically with Novartis and in the academic world at Duke University Medical Center and the University of North Carolina

Bill Silbey (portrait)

Bill Silbey

Executive Vice President & General Counsel

1959 – American

Bill Silbey

Executive Vice President & General Counsel

1959 – American

Joined UCB in 2011

Appointed in 2019

No external appointments

Experience

Over 35 years of experience in biopharmaceuticals legal affairs, mergers and acquisitions, business development and venture capital activities but also as partner in various U.S. Law Firms

Detlef Thielgen (portrait)

Detlef Thielgen

Executive Vice President, Chief Financial Officer & Corporate Development

1960 – German

Detlef Thielgen

Executive Vice President, Chief Financial Officer & Corporate Development

1960 – German

Joined UCB in 2006

Appointed in 2007

No external appointments

Experience

More than 25 years in the pharma industry with Schwarz Pharma and UCB, where he held several senior executive positions

Charl van Zyl (portrait)

Charl van Zyl

Executive Vice President Neurology Solutions & Head of EU/International

1967 – British/South African

Charl van Zyl

Executive Vice President Neurology Solutions & Head of EU/International

1967 – British/South African

Joined UCB in 2017

Appointed in 2017

Main external appointments

  • Member of the Board of BIO (Biotechnology Innovation Organization)

Experience

Almost 20 years of experience across the healthcare value chain, including business development and licensing, manufacturing, marketing and sales and research & clinical development

Xavier Michel, Group Secretary General, is acting as the secretary of the Executive Committee, ensuring the link between the Board of Directors, the Executive Committee and the broader organization.

Functioning of the Executive Committee

The Executive Committee met on a regular basis with an average of 2-3 days a month in 2019.

There were no transactions or contractual relationships in 2019 between UCB, including its affiliates, and a member of the Executive Committee.

The functioning, competences and authority of the Executive Committee are further described in the Charter.

Honorary chairmen of the Executive Committee

The following directors have been nominated as honorary chairman of the Executive Committee:

  • Roch Doliveux
  • Georges Jacobs de Hagen
  • Daniel Janssen

Relevant GRI Indicators

102-26 gri-id24:102-26